OKUR OnKure Therapeutics, Inc.

CIK 0001637715 49 ready 8-Ks latest June 4, 2026, 4:15 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 49

Latest filing June 4, 2026, 4:15 PM ET

Top materiality 1.00

Event mix other_material ×20 · earnings ×16 · leadership ×7

Sentiment 4 pos · 8 neg · 37 neu

Latest earnings reported 2026-Q1

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for OKUR

Highest-materiality recent filing

OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE

October 8, 2024, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 3.02 item 9.01 item 3.03 item 5.01 item 5.02 item 5.03 item 5.05 item 5.06 item 7.01 ◈ executive_change ×8◈ Governance Changes ×4

Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares.
PIPE investors subscribed for $65M, receiving 2,839,005 Class A shares; total Class A outstanding ~12.65M.

Read filing →

June 4, 2026, 4:15 PM ET other material materiality 0.55 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×3

Stockholders approve amended 2024 equity plan with 3.23M share increase and modified evergreen provision

Shareholders approved one-time increase of 3,231,638 shares (approx. 8% of outstanding) to the 2024 Equity Incentive Plan.
May 5, 2026, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

OnKure Q1 loss $15.2M; cash $192M; nominates two new PI3Kα inhibitors; halting OKI-219

Net loss of $15.2M ($1.11 per share) for Q1 2026 vs $15.9M ($1.19 per share) in Q1 2025.
March 30, 2026, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 3.02 item 5.02 item 8.01 item 9.01 ◈ Equity Issuances ×2◈ Material Agreements ×2

OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027

Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.
March 12, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts

Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.
November 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026

Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.
November 6, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

OnKure enters ATM offering agreement with Leerink Partners; up to 3% fee

Sales agreement with Leerink Partners for at-the-market offering of Class A common stock.
August 12, 2025, 7:59 PM ET other material materiality 0.65 neutral item 2.02 item 9.01

OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025

Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.
June 26, 2025, 7:59 PM ET other materiality 0.15 neutral item 7.01 item 9.01

OnKure Therapeutics posts updated corporate presentation to IR website

OnKure posted an updated corporate presentation on June 26, 2025.
May 28, 2025, 7:59 PM ET other material materiality 0.10 neutral item 5.07 item 9.01

OnKure shareholders elect Manke and Saccomano as Class I directors, ratify KPMG as auditor for FY2025

Dr. Isaac Manke elected with 4,589,481 for, 882,303 withheld; Dr. Nicholas Saccomano with 5,209,380 for, 262,404 withheld.
May 6, 2025, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01

OnKure Q1 net loss $15.9M, cash $96.7M; PIKture-01 trial on track for H2 2025 data

Net loss of $15.9M ($1.19 per share) vs $9.5M in Q1 2024; R&D expense rose to $13.0M.
March 10, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

OnKure Q4 2024 net loss $17.4M; cash $110.8M; PIKture-01 data in H2 2025

Net loss Q4 2024 $17.4M ($1.37/share) vs $9.5M ($30.14/share) in Q4 2023; R&D expense rose $5.6M.
December 10, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

OKI-219 well-tolerated in first human trial; no hyperglycemia, Part 1b combo initiated

17 patients dosed across 300–900 mg BID; no dose interruptions, reductions, or discontinuations.
November 7, 2024, 6:59 PM ET other material materiality 0.65 negative item 4.01 item 8.01 item 9.01 ◈ Auditor Changes ×2

Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger

Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.
October 8, 2024, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 3.02 item 9.01 item 3.03 item 5.01 item 5.02 item 5.03 item 5.05 item 5.06 item 7.01 ◈ executive_change ×8◈ Governance Changes ×4

OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE

Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares.
October 2, 2024, 7:59 PM ET M&A materiality 0.65 positive item 5.07

Reneo stockholders approve all proposals for OnKure merger at special meeting

Proposal 1 (stock issuance for merger) approved: 21.87M for, 110.6K against.
September 20, 2024, 7:59 PM ET litigation materiality 0.65 negative item 8.01

Reneo faces two shareholder lawsuits over OnKure merger proxy; provides supplemental disclosures

Two complaints filed in NY Supreme Court allege misrepresentations/omissions in proxy regarding financial projections and advisor conflicts.
September 13, 2024, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change

Reneo Pharma terminates CDO Ashley Hall amid planned merger with OnKure

Ashley F. Hall, Chief Development Officer, terminated effective Sept 13, 2024.
August 13, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024

Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.
May 13, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 1.01 item 3.02 item 5.01 item 5.02 item 7.01 item 9.01 ◈ executive_change ×3◈ Material Agreements

Reneo Pharma to merge with OnKure in reverse merger; OnKure stockholders to own 69.4% of combined company

OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.
May 7, 2024, 7:59 PM ET other material materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases

Reneo Pharmaceuticals initiates strategic alternatives review after failed trial; Q1 net loss $8.4M

STRIDE study of mavodelpar in primary mitochondrial myopathies missed all endpoints in Dec 2023.
March 28, 2024, 7:59 PM ET other material materiality 0.95 negative item 2.02 item 9.01 ◈ Earnings Releases

Reneo's pivotal STRIDE study misses endpoints; company cuts 90% workforce, explores strategic alternatives

STRIDE trial of mavodelpar in primary mitochondrial myopathy failed primary and secondary efficacy endpoints.
February 23, 2024, 6:59 PM ET other material materiality 0.65 negative item 2.05 ◈ Restructurings & Charges

Reneo Pharma to cut ~20% workforce, expects $1.7M severance charges in Q1 2024

Second workforce reduction of approximately 20% to be completed by February 29, 2024.
December 14, 2023, 6:59 PM ET other material materiality 0.90 negative item 2.05 item 8.01 ◈ Restructurings & Charges

Reneo's mavodelpar fails Phase 3 STRIDE study; cuts workforce 70%

Pivotal STRIDE trial of mavodelpar in primary mitochondrial myopathies missed primary endpoint (12MWT at week 24) and key secondary.
November 13, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Reneo Q3 net loss $19.2M; STRIDE topline results expected December 2023

Net loss of $19.2M ($0.57/sh) vs $13.0M ($0.53/sh) in Q3 2022; R&D expense up to $13.6M.
October 30, 2023, 7:59 PM ET other material materiality 0.50 neutral item 8.01

Reneo Pharmaceuticals repurchases 576,443 shares from vTv Therapeutics for $4.4M

Repurchased 576,443 shares at $7.64/share ($4.4M aggregate) from vTv Therapeutics LLC in a private transaction.
October 10, 2023, 7:59 PM ET other material materiality 0.75 neutral item 7.01 item 8.01 item 9.01

Reneo Pharma announces last patient last visit in pivotal STRIDE study; topline data expected Dec 2023

Last patient last visit completed in STRIDE study of mavodelpar for primary mitochondrial myopathies; topline data expected December 2023.
August 10, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Reneo Q2 net loss $19.5M; STRIDE topline results expected Q4 2023

Net loss $19.5M ($0.65/share) vs $12.3M ($0.50) in Q2 2022.
June 7, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

Reneo shareholders elect three Class III directors, ratify auditor at 2023 annual meeting

Elected all three Class III director nominees: Mathers 15.75M for, Muralidhar 15.42M for, Seltzer 15.94M for; 3.76M broker non-votes each.
May 11, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Reneo Pharma Q1 net loss $15.1M; STRIDE enrollment complete, topline 4Q23

Net loss of $15.1M ($0.60/sh) vs $13.0M ($0.53) in Q1 2022.
May 5, 2023, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements ×2

Reneo Pharmaceuticals prices public offering of 6.875M shares at $8.00, expects net proceeds ~$58.2M

Public offering of 6.875M shares at $8.00/share; underwriters exercised overallotment for 1.031M additional shares in full.
May 3, 2023, 7:59 PM ET other material materiality 0.60 positive item 2.02 item 7.01 item 8.01 item 9.01

Reneo Pharma reports $93.8M cash; enters non-binding term sheet for up to $100M royalty financing

Preliminary cash, cash equivalents and short-term investments of $93.8M as of March 31, 2023.
March 27, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Reneo reports Q4 2022 net loss $13.6M; STRIDE study enrollment complete

Full-year 2022 net loss $52.0M ($2.12 per share) vs $39.8M loss in 2021.
March 14, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01

Reneo achieves target enrollment in Phase 2b STRIDE trial of mavodelpar; topline Q4 2023

Target enrollment reached in global STRIDE study for mavodelpar in adult PMM patients.
March 10, 2023, 6:59 PM ET other material materiality 0.40 neutral item 7.01

Reneo Pharmaceuticals says SVB exposure immaterial; accounts hold minimal cash

Company maintains operating accounts at Silicon Valley Bank with minimal cash relative to total cash, cash equivalents and investments.
January 9, 2023, 6:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Reneo posts updated corporate presentation for JP Morgan Healthcare Conference; no specific details available

Presentation posted on company website and furnished as Exhibit 99.1; filing does not include slide content.
November 8, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Reneo reports Q3 net loss $13.0M, >80% enrolled in pivotal STRIDE study

Net loss of $13.0M ($0.53 per share) vs $12.7M ($0.52) in Q3 2021.
August 9, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Reneo Q2 net loss $12.3M; positive LC-FAOD results; STRIDE enrollment two-thirds

Net loss $12.3M ($0.50/share) vs $9.2M ($0.43/share) in Q2 2021.
August 2, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Reneo Pharmaceuticals appoints Roshawn Blunt as Class I director

Roshawn Blunt appointed as Class I director effective August 2, 2022, term expiring at 2025 annual meeting.
June 2, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

Reneo shareholders elect Dube and Hoelscher as Class I directors, ratify Ernst & Young as auditor

Annual Meeting held June 1, 2022; total outstanding shares 24,458,550.
May 10, 2022, 7:59 PM ET earnings materiality 0.50 neutral item 2.02 item 9.01

Reneo Q1 net loss $13.0M; STRIDE enrollment 50% done; LC-FAOD data in July 2022

Net loss of $13.0M ($0.53/share) vs $7.2M loss ($3.48/share) in Q1 2021.
March 23, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Reneo Pharma reports Q4 net loss $10.6M; cash $147.7M; no Phase 2 for McArdle

Net loss for Q4 2021 was $10.6M ($0.43 per share) vs $6.3M in Q4 2020; full year net loss $39.8M.
March 7, 2022, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Reneo appoints Michael P. Cruse as COO and Jennifer P. Lam as principal financial officer

Michael P. Cruse appointed COO effective March 2, 2022; base salary increased to $400K (from $350K) and bonus target to 40%.
February 2, 2022, 6:59 PM ET leadership materiality 0.65 negative item 5.02 ◈ executive_change

Reneo Pharmaceuticals CFO Vineet R. Jindal resigns, effective March 31, 2022

CFO Vineet R. Jindal notified resignation on Jan 28, 2022; effective March 31, 2022.
January 24, 2022, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change ×3

Reneo appoints Paul Hoelscher to board and audit committee chair; two directors exit

Paul Hoelscher appointed Class I director and Audit Committee Chair, effective Jan 20, 2022.
December 27, 2021, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Reneo Pharma CBO Wendy Johnson to depart Dec 31, enters consulting agreement

Wendy Johnson will cease as CBO on Dec 31, 2021; will serve as consultant for 18 months.
November 12, 2021, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Reneo Pharma Q3 2021 net loss $12.7M; cash $157.7M; trial progress

Net loss of $12.7M ($0.52/share) vs $5.1M ($2.48/share) in Q3 2020.
October 12, 2021, 7:59 PM ET leadership materiality 0.50 positive item 5.02 ◈ executive_change

Reneo Pharma appoints Ashley F. Hall as Chief Development Officer

Hall previously CDO at Esperion; oversaw regulatory for NEXLETOL, NEXLIZET, and REPATHA.
August 11, 2021, 7:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

Reneo Pharma Q2 net loss $9.2M vs $3.7M; cash $167.3M; STRIDE study first patient dosed

Net loss of $9.2M ($0.43/share) for Q2 2021, compared to net loss of $3.7M ($1.82/share) in Q2 2020.
August 11, 2021, 7:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Reneo Pharmaceuticals posts updated corporate slide deck for investor meetings

Presentation available on company website and filed as Exhibit 99.1 to Form 8-K.